Karydas Daphne sold $75K of MLYS
Karydas Daphne sold 3,000 shares of Mineralys Therapeutics, Inc. (MLYS) at $25.00 on 2026-06-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider ownership and confirms the sale was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may treat this as a routine ownership-change datapoint with limited immediate fundamental implications.
What to watch
The article provides only the sale size and plan type; it does not include total insider holdings changes beyond the post-transaction figure or any concurrent operational updates.
Background
This is an SEC Form 4 insider transaction disclosure for Mineralys Therapeutics, Inc.
Ticker impact
Director Karydas Daphne filed an open-market sale of 3,000 shares at $25/share under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless accompanied by other disclosures.
The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal—single insider sale does not change sector fundamentals.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of near-term risk; traders may watch for follow-on sales.
Key entities
- issuerMineralys Therapeutics, Inc.
Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.
- insiderKarydas Daphne
Director who executed the open-market sale of 3,000 shares.
